GlassScriptPhysician profile
Alesha Wilhelm
NPI 1265213649
$5,417.16
in general payments reported to CMS, 2019-2025
25 companies · $2,817 in 2025
The $2,817 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $189 · 2024: $2,411 · 2025: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,224 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,224.23 |
| Education | $192.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,059.10 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $607.54 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $601.01 | 2024-2025 | |
| Inspire Medical Systems, INC. | $415.08 | 2024-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $391.42 | 2023-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $362.61 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Amgen INC. | $258.10 | 2024-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $252.61 | 2024-2025 | Keytruda, Zerbaxa, Winrevair |
| Axsome Therapeutics, INC. | $220.29 | 2024-2025 | Sunosi |
| Verona Pharma, INC. | $213.02 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $160.73 | 2025 | Lumryz |
| Ani Pharmaceuticals, INC. | $140.52 | 2024-2025 | Purified Cortrophin Gel |
| Insmed, INC. | $132.68 | 2024-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $126.91 | 2024-2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $105.50 | 2023-2025 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| United Therapeutics Corporation | $57.62 | 2024-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $52.46 | 2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $50.52 | 2025 | |
| Idorsia Pharmaceuticals US INC | $31.74 | 2023-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $25.93 | 2025 | Mounjaro |
| Fisher & Paykel Healthcare INC | $23.64 | 2024 | Fisher & Paykel Healthcare |
| Viatris Specialty LLC | $22.10 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $14.28 | 2025 | |
| Baxter Healthcare | $12.76 | 2023 | Hillrom - Life 2000 Ventilation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alesha Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.